Rapamycin enhances the anti-cancer effect of Dasatinib by suppressing Src/PI3K/mTOR pathway in NSCLC cells

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Chen, Bin ^a,b   Xu, Xin ^a,b   Luo, Jie ^a,b   Wang, Heyong ^a,b   Zhou, Songwen ^a,b  

^a SHANGHAI PULMONARY HOSPITAL   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2D; CYCLIN E; DASATINIB; GELATINASE A; GELATINASE B; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; RAPAMYCIN; S6 KINASE; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; ANTINEOPLASTIC AGENT; CDK4 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

A549 CELL LINE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL INVASION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INACTIVATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; LUNG CANCER CELL LINE; MIGRATION INHIBITION; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; UPREGULATION; APOPTOSIS; CELL CYCLE; DRUG EFFECTS; GENETICS; LUNG TUMOR; METABOLISM; SECOND MESSENGER; TUMOR CELL LINE;

MAMMALIA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; DASATINIB; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LUNG NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SECOND MESSENGER SYSTEMS; SRC-FAMILY KINASES; TOR SERINE-THREONINE KINASES;

EID: 84936855517     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129663     Document Type: Article

References (48)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015, 136: E359-386. doi: 10.1002/ijc.29210 PMID: 25220842
2. Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin YJ, et al. pp60c-src activation in lung adenocarcinoma. Eur J Cancer. 2003, 39: 1447-1455. PMID: 12826049
3. Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, et al. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol. 2007, 170: 366-376. PMID: 17200208
4. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009, 6: 587-595. doi: 10.1038/nrclinonc.2009.129 PMID: 19787002
5. Sen B, Johnson FM. Regulation of SRC family kinases in human cancers. J Signal Transduct. 2011, 2011: 865819. doi: 10.1155/2011/865819 PMID: 21776389
6. Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, et al. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res. 2012, 18: 3580-3591. doi: 10.1158/1078-0432.CCR-11-3359 PMID: 22586301
7. Nautiyal J, Majumder P, Patel BB, Lee FY, Majumdar AP. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett. 2009, 283: 143-151. doi: 10.1016/j.canlet.2009.03.035 PMID: 19398150
8. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006, 66: 5542-5548. PMID: 16740687
9. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res. 2005, 11: 6924-6932. PMID: 16203784
10. Miller AA, Pang H, Hodgson L, Ramnath N, Otterson GA, Kelley MJ, et al. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol. 2010, 5: 380-384. doi: 10.1097/JTO.0b013e3181cee36e PMID: 20087228
11. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, et al. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010, 28: 4609-4615. doi: 10.1200/JCO.2010.30.5474 PMID: 20855820
12. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, et al. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res. 2009, 69: 3842-3849. doi: 10.1158/0008-5472.CAN-08-2246 PMID: 19383922
13. Ceppi P, Papotti M, Monica V, Lo Iacono M, Saviozzi S, Pautasso M, et al. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. Mol Cancer Ther. 2009, 8: 3066-3074. doi: 10.1158/1535-7163.MCT-09-0151 PMID: 19861409
14. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010, 28: 1387-1394. doi: 10.1200/JCO.2009.25.4029 PMID: 20142592
15. Raju U, Riesterer O, Wang ZQ, Molkentine DP, Molkentine JM, Johnson FM, et al. Dasatinib, a multikinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Radiother Oncol. 2012, 105: 241-249. doi: 10.1016/j.radonc.2012.08.010 PMID: 23010482
16. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012, 149: 274-293. doi: 10.1016/j.cell.2012.03.017 PMID: 22500797
17. Gridelli C, Maione P, Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist. 2008, 13: 139-147. doi: 10.1634/theoncologist.2007-0171 PMID: 18305058
18. Marinov M, Fischer B, Arcaro A. Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol. 2007, 63: 172-182. PMID: 17540577
19. Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol. 2012, 7: 1315-1326. doi: 10.1097/JTO.0b013e31825493eb PMID: 22648207
20. Nagata Y, Takahashi A, Ohnishi K, Ota I, Ohnishi T, Tojo T, et al. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status. Int J Oncol. 2010, 37: 1001-1010. PMID: 20811722
21. Tomioka H, Mukohara T, Kataoka Y, Ekyalongo RC, Funakoshi Y, Imai Y, et al. Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification. Int J Oncol. 2012, 41: 551-558. doi: 10.3892/ijo.2012.1485 PMID: 22614071
22. Song JJ, Kim JH, Sun BK, Alcala MA Jr., Bartlett DL, Lee YJ. c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment. Cell Signal. 2010, 22: 377-385. doi: 10.1016/j.cellsig.2009.10.007 PMID: 19861161
23. Jin W, Yun C, Jeong J, Park Y, Lee HD, Kim SJ. c-Src is required for tropomyosin receptor kinase C (TrkC)-induced activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. J Biol Chem. 2008, 283: 1391-1400. PMID: 17991742
24. Choudhury GG, Mahimainathan L, Das F, Venkatesan B, Ghosh-Choudhury N. c-Src couples PI 3 kinase/Akt and MAPK signaling to PDGF-induced DNA synthesis in mesangial cells. Cell Signal. 2006, 18: 1854-1864. PMID: 16530387
25. Wang X, Lin C, Zhao X, Liu A, Zhu J, Li X, et al. Acylglycerol kinase promotes cell proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Mol Cancer. 2014, 13: 106. doi: 10.1186/1476-4598-13-106 PMID: 24886245
26. Boehrer S, Galluzzi L, Lainey E, Bouteloup C, Tailler M, Harper F, et al. Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. Cell Cycle. 2011, 10: 3168-3175. PMID: 21897118
27. Aoki M, Jiang H, Vogt PK. Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci U S A. 2004, 101: 13613-13617. PMID: 15342912
28. Roediger J, Hessenkemper W, Bartsch S, Manvelyan M, Huettner SS, Liehr T, et al. Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway. Mol Cancer. 2014, 13: 214. doi: 10.1186/1476-4598-13-214 PMID: 25216853
29. Li XY, Jiang LJ, Chen L, Ding ML, Guo HZ, Zhang W, et al. RIG-I modulates Src-mediated AKT activation to restrain leukemic stemness. Mol Cell. 2014, 53: 407-419. doi: 10.1016/j.molcel.2013.12.008 PMID: 24412064
30. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002, 2: 489-501. PMID: 12094235
31. Lee H, Kim JS, Kim E. Fucoidan from seaweed Fucus vesiculosus inhibits migration and invasion of human lung cancer cell via PI3K-Akt-mTOR pathways. PLoS One. 2012, 7: e50624. doi: 10.1371/journal.pone.0050624 PMID: 23226337
32. Li C, Li F, Zhao K, Yao J, Cheng Y, Zhao L, et al. LFG-500 inhibits the invasion of cancer cells via down-regulation of PI3K/AKT/NF-kappaB signaling pathway. PLoS One. 2014, 9: e91332. doi: 10.1371/journal.pone.0091332 PMID: 24618693
33. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008, 68: 3645-3654. doi: 10.1158/0008-5472.CAN-07-2938 PMID: 18483246
34. Lau MT, So WK, Leung PC. Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS One. 2013, 8: e59083. doi: 10.1371/journal.pone.0059083 PMID: 23554977
35. Brouxhon SM, Kyrkanides S, Teng X, Athar M, Ghazizadeh S, Simon M, et al. Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling. Oncogene. 2014, 33: 225-235. doi: 10.1038/onc.2012.563 PMID: 23318419
36. Yang YL, Chen MW, Xian L. Prognostic and clinicopathological significance of downregulated E-cadherin expression in patients with non-small cell lung cancer (NSCLC): a meta-analysis. PLoS One. 2014, 9: e99763. doi: 10.1371/journal.pone.0099763 PMID: 24978478
37. Peiro G, Ortiz-Martinez F, Gallardo A, Perez-Balaguer A, Sanchez-Paya J, Ponce JJ, et al. Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. Br J Cancer. 2014, 111: 689-695. doi: 10.1038/bjc.2014.327 PMID: 24937674
38. Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, et al. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res. 2012, 18: 5911-5923. doi: 10.1158/1078-0432.CCR-12-1257 PMID: 22896656
39. Inge LJ, Fowler AJ, Paquette KM, Richer AL, Tran N, Bremner RM. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia. J Thorac Cardiovasc Surg. 2013, 145: 531-538. doi: 10.1016/j.jtcvs.2012.10.041 PMID: 23142123
40. Indovina P, Giorgi F, Rizzo V, Khadang B, Schenone S, Di Marzo D, et al. New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization. Oncogene. 2012, 31: 929-938. doi: 10.1038/onc.2011.286 PMID: 21785466
41. Watanabe T, Tsuda M, Tanaka S, Ohba Y, Kawaguchi H, Majima T, et al. Adaptor protein Crk induces Src-dependent activation of p38 MAPK in regulation of synovial sarcoma cell proliferation. Mol Cancer Res. 2009, 7: 1582-1592. doi: 10.1158/1541-7786.MCR-09-0064 PMID: 19737974
42. Cao D, Bromberg PA, Samet JM. Diesel particle-induced transcriptional expression of p21 involves activation of EGFR, Src, and Stat3. Am J Respir Cell Mol Biol. 2010, 42: 88-95. doi: 10.1165/rcmb.2008-0455OC PMID: 19329556
43. Leontieva OV, Blagosklonny MV. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion. Cell Cycle. 2013, 12: 3063-3069. doi: 10.4161/cc.26130 PMID: 23974099
44. Dalvai M, Schubart K, Besson A, Matthias P. Oct1 is required for mTOR-induced G1 cell cycle arrest via the control of p27(Kip1) expression. Cell Cycle. 2010, 9: 3933-3944. PMID: 20935455
45. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005, 65: 7052-7058. PMID: 16103051
46. Demers MJ, Thibodeau S, Noel D, Fujita N, Tsuruo T, Gauthier R, et al. Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1. J Cell Biochem. 2009, 107: 639-654. doi: 10.1002/jcb.22131 PMID: 19479902
47. Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther. 2010, 9: 592-603. PMID: 20139705
48. Johnson ML, Riely GJ, Rizvi NA, Azzoli CG, Kris MG, Sima CS, et al. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. J Thorac Oncol. 2011, 6: 1128-1131. doi: 10.1097/JTO.0b013e3182161508 PMID: 21623279